¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"reserve model"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • health belief model
    °Ç°­¹ÏÀ½¸ðÇü
  • homeostatic model
    Ç׻󼺸ðÇü
  • in-the-ear model
    ±Ó¼Óº¸Ã»±â
  • model
    ¸ðÇü, ¸ðµ¨
  • model population
    ¸ðÇüÀα¸
  • model psychosis
    ¸ðÇüÁ¤½Åº´
  • multiple logistic model
    ´ÙÁß·ÎÁö½ºÆ½¸ðÇü
  • multiplicative model
    °ö¼À¸ðÇü
  • multistage model
    ´Ù´Ü°è¸ðÇü
  • multitarget model
    ´ÙÇ¥Àû¸ðµ¨
  • multitarget multihit model
    ´ÙÇ¥Àû´ÙÀûÁ߸ðµ¨
  • multitarget single hit model
    ´ÙÇ¥Àû´ÜÀÏÀûÁ߸ðµ¨
  • organic model
    À¯±â¸ðÇü
  • plaster model
    ¼®°í¸ðÇü
  • proportional hazards model
    ºñ·ÊÀ§Çè¸ðÇü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • general linear model
    ÀϹݼ±»ó¸ðµ¨
  • gnathostatic model
    ÅθðÇü, ¾ÇŸðÇü
  • health belief model
    °Ç°­¹ÏÀ½¸ðÇü
  • homeostatic model
    Ç׻󼺸ðÇü
  • in-the-ear model
    ±Í¼ÓÇüº¸Ã»±â
  • linear quadratic model
    ¼±Çü¹æÇü¸ðµ¨, ¼±ÇüÀÌÂ÷ÇÔ¼ö¸ðµ¨
  • model
    ¸ðÇü, ¸ðµ¨
  • model population
    ¸ðÇüÀα¸
  • model psychosis
    ¸ðÇüÁ¤½Åº´
  • multiple logistic model
    ´ÙÁß·ÎÁö½ºÆ½¸ðÇü
  • multistage model
    ´Ù´Ü°è¸ðÇü
  • multitarget model
    ´ÙÇ¥Àû¸ðµ¨
  • multitarget multihit model
    ´ÙÇ¥Àû´ÙÀûÁ߸ðµ¨
  • multitarget single hit model
    ´ÙÇ¥Àû´ÜÀÏÀûÁ߸ðµ¨
  • mutiplicative model
    °ö¼À¸ðÇü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • ventilation reserve
    ȯ±â¿¹ºñ´É.
  • absolute risk model
    Àý´ëÀ§Çè¸ðµ¨
  • atomic model
    ¿øÀÚ¸ðÇü(¡­Ù¼úþ).
  • biopsychological model
    »ýü½É¸®ÇÐÀû ¸ðµ¨
  • bulk phase model
    µ¢¾î¸® À§»ó ¸ðÇü
  • compartmentalization model
    ±¸È¹È­ ¸ðÇü
  • core conductor model
    ÇÙÀüµµÃ¼¸ðÇü(ú·ï³Óôô÷Ù¼úþ).
  • developmental model
    ¹ß´Þ(Û¡Ó¹)¸ðÇü
  • double helix, DNA model
  • ear model(ITE), in the
    ±Í¼ÓÇü(º¸Ã»±â)
  • fluid mosaic model
    À¯µ¿(×µÔÑ)¸ðÀÚÀÌÅ©¸ðµ¨.
  • fluid mosaic model
    À¯µ¿¼º ¸ðÀÚÀÌÅ© ¸ðµ¨
  • general linear model
    ÀϹÝÀû ¼±Çü ¸ðµ¨, ÀÏ¹Ý ¼±»ó ¸ðµ¨
  • gnathostatic model
    ¾ÇŸðÇü(¡­Ù¼úþ).
  • health belief model
    °Ç°­¹ÏÀ½ ¸ðÇü.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • knife and fork model
    ³ªÀÌÇÁÆ÷Å© ¸ðµ¨
  • "Koshland, Nemethy, and Filmer model"
    "ÄÚ½¬·»µå,³×¸ÞƼ,ÇÊ¸Ó ¸ðµ¨"
  • leaky patch model
    ´©Ãâ(שõó) ÆäÄ¡¸ðµ¨
  • lethal mutation model
    Ä¡»çº¯ÀÌ(öÈÞÝܨì¶)¸ðµ¨
  • lipid-globular protein mosaic model
    "ÁöÁú-±¸»ó´Ü¹éÁú(ò·òõϹßÒÓ±ÛÜòõ) , ¸ðÀÚÀÌÅ©¸ðµ¨"
  • looped rolling circle model
    ·çÇÁÇü ȸÀü¿ø(üÞï®ê­)¸ðµ¨
  • master-slave model
    ÁÖÁ¾(ñ«ðô) ¸ðµ¨
  • mobile receptor model
    À̵¿¼ö¿ëü(ì¹ÔÑáôé»ô÷) ¸ðµ¨
  • model
    ¸ðµ¨
  • model system
    ¸ðµ¨½Ã½ºÅÛ
  • "Monod, Wyman, and Changeux model"
    ¸ð³ë.¿ÍÀ̸¸.¼§Á¶¸ðµ¨
  • MWC model
    "(å²) Monod, Wyman and Changeux ¸ðµ¨"
  • nearest-neighbor cooperative model
    ÃÖ±ÙÁ¢ Çùµ¿(õÌÐÎïÈúðÔÒ) ¸ðµ¨
  • nearest-neighbor exclusion model
    ÃÖ±ÙÁ¢ ¹èÁ¦(õÌÐÎïÈÛÉð¶) ¸ðµ¨
  • opposing rolling circle model
    ¿ªÈ¸Àü ¿øÇü(æ½üÞï®ê­û¡) ¸ðµ¨
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PDM point distribution model
PRECEDE predisposing, reinforcing, and enabling causes in educational diagnosis and evaluation [model]
PROC GLM general linear model procedure
RA radioactive; ragocyte; ragweed antigen; rapidly adapting [receptors]; reactive arthritis; reciprocal...
RCM radial contour model; radiographic contrast medium; red cell mass; reinforced clostridial medium; re...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
FFM Five Factor Model
FLMP Fuzzy Logical Model of Perception
GLM General Linear Model
GLM Generalised Linear Model
HBM Health Belief Model
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
multiplicative model A model in which the joint effect of two or more causes is the product of their effects if they were acting alone.
(05 Mar 2000)
multistage model A mathematical model, mainly for carcinogenesis, based on the theory that a specific carcinogen may affect one among a number of stages in the development of cancer.
(05 Mar 2000)
continuous time model <epidemiology> A model in which the system changes continuously over time. Derivatives (e.g. DY/dt ) are the mathematical formalism for describing such continuous change. The differential equation which embodies a model provides the values of these derivatives at any particular time point; calculus or a computer can then be used to move the state of the model forwards in time.
Continuous models have the advantage over discrete time models in that they are more amenable to algebraic manipulation, although they are slightly harder to implement on a computer.
The same as a differential equation model.
(05 Dec 1998)
cooperativity model A model used to explain the property of cooperativity observed in certain enzymes; e.g., allosterism or hysteresis.
(05 Mar 2000)
seir model <epidemiology> A class of compartmental prevalence models, with compartments Susceptible, Latent (Exposed), Infectious and Recovered. Takes its name from a common notation. In the notation used in the course, this would be an XHYZ model. Many permutations possible.
(05 Dec 1998)
sliding filament model <cell biology> Generally accepted model for the way in which contraction occurs in the sarcomere of striated muscle, by the sliding of the thick filaments relative to the thin filaments.
(18 Nov 1997)
spawner-recruit model Biological model that relates the number of recruits or mature spawners in one generation to the number of spawners in the previous generation.
(09 Oct 1997)
statistical model A formal representation for a class of processes that allows a means of analyzing results from experimental studies, such as the Poisson model or the general linear model; it need not propose a process literally interpretable in the context of the individual case.
(05 Mar 2000)
stochastic model <epidemiology> A mathematical model which takes into consideration the presence of some randomness in one or more of its parameters or variables. The predictions of the model therefore do not give a single point estimate but a probability distribution of possible estimates. Contrast with deterministic.
We might distinguish demographic stochasticity which arises from the discreteness of individuals and individual events such as birth, and environmental stochasticity arising from more-or-less unpredictable interactions with the outside world.
(05 Dec 1998)
nursing model A set of abstract and general statements about the concepts that serve to provide a framework for organizing ideas about clients, their environment, health and nursing.
(05 Mar 2000)
surface envelope model <biology> A way of treating the hydrodynamics of a ciliary field by considering the whole surface of the ciliate to have an undulating surface. The undulations arise because of metachronism.
(18 Nov 1997)
deterministic model <epidemiology> A mathematical model in which the parameters and variables are not subject to random fluctuations, so that the system is at any time entirely defined by the initial conditions chosen. Contrast with a stochastic model.
(05 Dec 1998)
discrete time model <epidemiology> A model in which the system jumps from one state to the next at fixed intervals or timesteps. These difference models are simple to understand but often difficult to analyse; Contrast continuous time models.
The parameters in such a model refer to the amount of change over the finite timestep; they are sometimes referred to as finite rates.
In a (rather precise) sense, a differential equation is what you eventually get from a difference equation when you let the timestep get smaller and smaller and smaller.
(05 Dec 1998)
induced fit model A model to suggest a mode of action of enzymes in which the substrate binds to the active site of the protein, causing a conformational change in the protein.
Synonym: Koshland-Nemethy-Filmer model.
(05 Mar 2000)
transition probability model A model to account for the apparently random variation in cell cycle time between individual animal tissue cells in culture that postulates that transition from G1 to s phase is probabilistic. Contrasts with hypotheses that require the accumulation of critical levels of particular proteins.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • ready reserve
    ¿¹ºñ±º
  • reserve
    (Èʳ¯À» À§ÇÏ¿©)³²°Ü(¶¼¾î)µÎ´Ù;(Á¼®.¹æ µîÀ»)¿¹¾àÇØ µÎ´Ù;ÁöÁ¤ÇÏ´Ù;È®º¸ÇØ µÎ´Ù;´ÙÀ½À¸·Î ³Ñ±â´Ù;ÀÌ¿ù(¿¬±â)ÇÏ´Ù(postpond);»ï°¡´Ù;»ç¾çÇÏ´Ù;º¸À¯ÇÏ´Ù;º¸·ùÇÏ´Ù;(¾î¶² ±ÇÀÍ.Á¶¾àÀÇ Àû¿ë µîÀ»)À¯º¸ÇÏ´Ù;Á¦¿ÜÇÏ´Ù;(¼ºÃ¼.¼ºÂùÀÇ ÀϺθ¦)³²°ÜµÎ´Ù;¿î¸íÁþ´Ù;ÀúÃà;¿©Ãà;º¸Á¸¹°;¿¹
  • reserve bank
    ¿¬¹æ Áغñ ÀºÇà
  • reserve card
    µµ¼­ ´ëÃâ ÅëÁö¼­(Àü¿¡ ½ÅûÇÑ Ã¥ÀÌ ´ëÃâ °¡´ÉÇÔÀ» ¾Ë¸®´Â)
  • reserve clause
    º¸·ùÁ¶Ç×(ÇÁ·Î½ºÆ÷Ã÷ ¼±¼öÀÇ ÀÌÀû¿¡ °üÇÑ °è¾à Á¶Ç×)
  • reserve price
    ÃÖÀú °æ¸Å °¡°Ý
  • reserve ration
    ¿¹ºñ ½Ä·®(¹ÐÆó ¿ë±â¿¡ Æ÷ÀåÇÑ ³óÃà ½Ä·®.À¯»ç½Ã¿¡ »ç¿ë)
  • reserve tranche
    ¸®Àúºê Æ®¶û½´(IMF°¡¸Í±¹ÀÌ ÃâÀÚ¾× Áß 25%¿¡ ÇØ´çÇÏ´Â ¿ÜÈ­¸¦ ÀÚÀ¯·Ó°Ô ²¨³¾ ¼ö ÀÖ´Â ºÎºÐ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á